The debate behind The $6 Million Verdict That Could Cost Silicon Valley Billions — And Why It Should

Response to Advocate A: Where the Framework Is Legally Sound But Practically Dangerous

Identifying and Challenging the Weakest Point: The "Knowing Harm" Analogy

Advocate A's most rhetorically powerful but empirically weakest claim is the pharmaceutical analogy — that platforms deliberately engineering harm for minors is analogous to drug companies targeting vulnerable populations. This analogy breaks down on the specific causation evidence, and that matters legally.

The internal documents establish correlation concerns, not established causation. The 2021 Senate hearings featured Meta's internal research, but that research has been significantly mischaracterized in public discourse. The actual slide deck, reviewed by independent researchers including Candice Odgers (University of California, Irvine), found that Meta's own data showed correlation between heavy Instagram use and negative self-reported mood — but Odgers, whose work on adolescent technology use spans decades, wrote explicitly in Nature (2018) that "the idea that smartphones and social media are harming teenagers is not supported by the evidence." A 2022 preregistered study by Orben, Przybylski, and colleagues in Nature Human Behaviour found that the effect size of social media on adolescent wellbeing was comparable to wearing glasses or eating potatoes — statistically detectable but substantively trivial.

This is not a defense of Meta's conduct. It is a challenge to A's specific framing: if the underlying causal chain is scientifically contested, building a tort liability framework premised on that chain as established fact will produce verdicts that are legally operational but empirically unfounded. Juries cannot adjudicate neuroscience; they respond to compelling narratives. That is precisely the problem.

---

My Affirmative Case

1. Tort Liability for Design Choices Creates Perverse Moderation Incentives — With Historical Precedent

When liability attaches to algorithmic curation decisions, the rational corporate response is not better curation — it is less curation. This is not speculation; it has a documented analog. After FOSTA-SESTA (2018) exposed platforms to sex trafficking liability, the Electronic Frontier Foundation documented a wave of over-cautious content removal affecting consensual adult sex workers, LGBTQ+ health resources, and harm-reduction communities. Platforms did not surgically remove bad actors; they removed entire categories of content to minimize litigation exposure.

The mechanism here is straightforward: if recommending content to minors creates tort exposure, the safest legal posture is either (a) aggressive age-gating that is trivially bypassed and merely redistributes liability, or (b) recommending only content so anodyne that engagement collapses and the platform becomes unusable. Neither outcome protects minors. Both demonstrably harm adult users and minority communities whose content gets caught in the over-removal net.

2. The Lemmon v. Snap Template Does Not Actually Support A's Framework — It Illustrates Its Limits

Advocate A cites Lemmon approvingly, but the factual basis of that case is instructively different. The Snap Speed Filter was a feature with a direct and proximate causal mechanism: it displayed a user's real-time speed, incentivizing dangerous driving that caused specific deaths. The causal chain was: feature → behavior → injury, with no intervening variables. That is traditional product liability territory.

The algorithmic recommendation case is structurally different. The causal chain is: feature → content exposure → psychological processing → voluntary behavior → harm. That chain includes multiple intervening human choices and is mediated by individual psychology, family environment, pre-existing mental health conditions, and peer dynamics. A legal framework that cannot distinguish these causal structures will apply the same liability standard to Snap's speed feature and to YouTube recommending cooking videos to a teenager who already has an eating disorder — because both involve algorithmic personalization to minors.

Stretching product liability doctrine this far does not refine the law. It makes it unpredictable.

3. The "Legislature Versus Judiciary" Problem Is Structural, Not Rhetorical

Advocate A's framing implicitly trusts courts to calibrate this liability framework correctly over time through common law development. The structural problem is that algorithmic systems are not static products — they are continuously updated, A/B tested systems whose causal effects are deeply context-dependent. Legislatures can hold hearings, commission expert panels, and write prospective rules with safe harbors. Courts cannot. They adjudicate backward-looking disputes with adversarial expert witnesses and lay juries.

The EU's Digital Services Act, enacted 2022, imposes direct regulatory obligations on very large online platforms regarding algorithmic transparency and minor protection — without creating open-ended private tort liability. That is a coherent alternative: prospective, expert-driven, democratically accountable regulation, rather than retroactive liability that empowers any plaintiff's attorney to second-guess every engineering decision a platform made five years ago. The existence of that alternative makes the tort liability route not merely risky but unnecessary.

Round 2 Response: Pressing on A's Concessions and the Remaining Structural Problems

Where Advocate A Conceded Ground — and What That Implies

Advocate A made two significant concessions that deserve to be foregrounded before proceeding.

First, A explicitly acknowledged that the causal science is "genuinely contested in ways that complicate 'knowing harm' arguments." This is not a minor qualification. A's entire Round 1 framework was built on the claim that platforms engaged in "knowing disregard for foreseeable harm" — language that imports a high degree of causal certainty. By conceding the science is contested, A has implicitly admitted that the "knowing harm" standard will not be consistently applicable across the hundreds of pending cases in the MDL. If the underlying causal chain is scientifically contested at the population level, then plaintiffs in cases without access to the same specific internal documents Meta produced will face exactly the empirically unfounded verdicts I warned about: juries adjudicating contested neuroscience through the lens of compelling plaintiff narratives, not established science.

Second, A conceded the Lemmon v. Snap distinction is "a legitimate legal concern, not a rhetorical dodge." This matters because Lemmon was A's primary legal precedent in Round 1. A now acknowledges it does not straightforwardly support the algorithmic recommendation liability framework. That is a meaningful retreat from A's opening position.

A's attempt to recover from these concessions relies on a single pivot: the internal corporate documents, A argues, "collapsed the causal uncertainty" by showing specific foreknowledge of specific harm to identifiable subpopulations. This is where I will focus, because it is where the argument is weakest.

---

Why the "Internal Documents Collapse Causal Uncertainty" Argument Fails as a General Framework

A's pivot to internal documents is rhetorically effective in this specific case but legally dangerous as a general framework. Here is why.

The argument proves too much in some cases and too little in others. If tort liability for design choices turns on whether a company possesses internal research flagging potential harms to users, then every major technology company — indeed, every major company of any kind — that conducts honest internal safety research becomes more legally exposed than companies that do not. The incentive structure this creates is well-documented in the pharmaceutical literature: after Daubert tightened scientific admissibility standards and litigation risk rose, pharmaceutical companies systematically reduced internal safety research to limit discoverable adverse findings. See Kesselheim & Avorn, "The Role of Litigation in Defining Drug Risks," JAMA (2007). A tort framework that punishes documented internal awareness of risk over ignorance will predictably reduce internal safety research in Silicon Valley, leaving regulators and courts with less evidence about harm, not more. That is the opposite of what A intends.

A's "top decile" argument narrows the framework in a way that creates its own problems. A argues that liability is specifically grounded in Meta's internal finding that teenage girls in the top decile of usage showed elevated negative outcomes. But this creates an immediate practical question: how does a jury or court identify, in advance, which users will fall into the top usage decile? The recommendation algorithm does not know in real time that a given minor will become a heavy user. It is optimizing for engagement across a population. If the tortious act is designing for engagement without knowing which users will become top-decile users, then the liability attaches to the design choice broadly — and A has not explained how this avoids the over-cautious design response I identified.

Stated differently: if platforms cannot predict which minors will become heavy users at the time of design, and liability attaches when heavy users are harmed, then the legally safe design is to not optimize engagement for any minor users — which is the broad, anodyne outcome I described in Round 1.

---

A's DSA Rebuttal Does Not Hold

A argues that tort liability and regulatory frameworks are "not mutually exclusive" and cites the pharmaceutical industry's simultaneous operation under FDA regulation and product liability law. This analogy requires examination.

The pharmaceutical analogy actually undermines A's position on this specific point. The pharmaceutical dual-track system — FDA regulation plus tort liability — has produced a well-documented "liability gap" problem: because regulatory compliance does not automatically preempt tort suits, pharmaceutical companies have faced massive liability exposure for products that passed FDA review, creating what economists at the Brookings Institution have called a "chilling effect on innovation in therapeutic areas with high litigation risk." See Huber, "Liability: The Legal Revolution and Its Consequences" (1988); more recently, Viscusi & Born, "Damages Caps, Insurability, and the Performance of Medical Malpractice Insurance," Journal of Risk and Insurance (2005). The FDA-plus-tort dual track is not a model to emulate — it is a cautionary tale about the friction between prospective expert regulation and retroactive lay adjudication.

More importantly, A mischaracterizes my DSA argument. I did not claim the DSA makes tort liability illegitimate for past harms — I claimed it makes the open-ended tort liability template being established now unnecessary as a forward-looking framework. A's own acknowledgment that the DSA "lacks private right of action" and is "prospective" is correct. But the appropriate response to that gap is to build private right of action into prospective legislation — with defined standards, safe harbors, and causation thresholds that expert legislators can calibrate — not to let common law tort doctrine fill that gap through backward-looking jury verdicts. Congressional action on KOSA (Kids Online Safety Act) and the EU's legislative pathway both demonstrate this is politically achievable. A has offered no response to this specific point.

---

The Core Structural Problem A Has Not Answered

I want to be precise about what A's framework, even as refined in Round 2, cannot resolve.

A's position requires courts and juries to make three determinations in each case:

1. Whether a specific design choice (algorithmic weighting) was the proximate cause of harm, given a multi-step causal chain with documented scientific uncertainty at multiple links.
2. Whether internal corporate documents in a given case rise to the level of "specific foreknowledge of specific harm to identifiable subpopulations."
3. Whether a given plaintiff falls within the subpopulation about which the company had foreknowledge.

These determinations require scientific expertise, access to proprietary corporate research, and calibrated judgment about statistical evidence. Juries, as currently constituted, are not equipped to make these determinations reliably. The result will not be consistent, well-calibrated liability that targets the worst corporate behavior — it will be variable, plaintiff-narrative-driven outcomes that large platforms can manage through settlement and that smaller competitors cannot afford to litigate at all. The beneficiaries of this framework are not harmed minors. They are plaintiffs' attorneys and incumbent platforms large enough to absorb settlement costs while smaller entrants cannot.

A has not addressed this structural point at all. The incumbency protection effect of complex tort liability — well-documented in the legal economics literature, including work by Steven Shavell at Harvard Law School — means that the template being established here will entrench Meta and YouTube as dominant platforms by raising barriers to entry for potential competitors, while providing only probabilistic, inconsistent compensation to harmed plaintiffs. That is a poor trade.

---

Summary

A's Round 2 concessions are consequential: the causal science is contested, the primary legal precedent is distinguishable, and the "internal documents" pivot creates incentives that will reduce corporate safety research industry-wide. The forward-looking alternative — prospective legislation with defined standards, expert input, and private rights of action — addresses both past harm (through directed statutory remedies) and future design choices (through clear, predictable rules) without handing lay juries the authority to adjudicate algorithmic engineering decisions under contested scientific premises. A has not engaged with this alternative on its merits. Until they do, the structural case for this tort liability template remains unmet.

Round 3: Steel-Man, Defense, and Conditions for Changing My Mind

---

Steel-Manning Advocate A

The strongest version of A's position is this: the tort liability template is not an exercise in abstract policy design — it is a response to a decade-long regulatory vacuum that the platforms themselves helped create through lobbying, and it rests on a specific and unusual evidentiary predicate: companies whose own internal researchers documented harm to identifiable minor populations, whose executives received those findings, and who continued optimizing the harmful design features anyway. In that narrow factual context, asking a jury to evaluate what a company knew and chose to do — rather than to adjudicate contested population-level neuroscience — is precisely what product liability law exists to do, and it is the only instrument currently capable of compensating specific harmed individuals that no regulatory process has reached. Courts built modern products liability doctrine from scratch in cases like Greenman v. Yuba Power Products (1963) and Grimshaw v. Ford Motor Co. (1981), and those precedents, which seemed disruptively novel at the time, produced genuine behavioral change in industries that resisted legislative oversight. The discomfort of novel doctrine is not evidence the doctrine is wrong.

That is a serious position. It does not defend Meta's conduct — it makes a claim about institutional necessity under conditions of regulatory failure. I want to engage with it honestly.

---

Why My Position Holds Despite A's Best Argument

A's strongest argument is also its most contingent one, and Round 3 has sharpened exactly where it is contingent.

First, A's "manageable evidentiary standard" claim deserves direct scrutiny. A argues in Round 3 that juries are not being asked to adjudicate contested neuroscience — only to evaluate "what a company knew and chose to do." This reframing is cleaner than A's Round 1 position, but it does not hold under examination. To find negligent design, a jury must find not only that the company had internal knowledge of potential harm, but that the design choice was unreasonably dangerous given that knowledge — which requires the jury to assess whether the risk was real and substantial, not merely flagged internally. Meta's own researchers flagged concerns; they did not conclude that Instagram caused clinical-level harm to teenage girls as a matter of established science. The gap between "internal researchers noted a correlation and recommended further study" and "the design was unreasonably dangerous" is precisely where contested epidemiology enters the verdict room — because jurors must assess the magnitude of the risk to evaluate reasonableness. A has not closed that gap; A has papered over it.

Second, A's concession that the "reduced safety research" incentive is "directionally uncertain" is more significant than A acknowledges. A argues the tort model incentivizes platforms to study harm and document mitigation. This is theoretically possible but empirically unsupported in the present context. The mechanism A describes — "you want to document that you identified the problem and fixed it" — only functions if there is a clear, legally recognized safe harbor for compliant conduct. There is not one in this tort framework. The current template, as established by the verdict, provides no defined standard a platform could meet to avoid liability for algorithmic recommendations to minors. Without a safe harbor, the incentive is not to study and fix — it is to avoid creating discoverable evidence of awareness, which is the adverse direction the pharmaceutical literature documents. A's preferred incentive structure requires legislative drafting that A simultaneously argues we should not wait for. That is an internal tension A has not resolved.

Third, on the "regulatory vacuum" argument: A is correct that KOSA has stalled and the DSA lacks private right of action. I do not dispute the factual record on legislative delay. But A draws the wrong inference. The correct response to legislative delay caused by platform lobbying is to address that lobbying through campaign finance and lobbying reform, and to build legislative coalitions — not to route around democratic deliberation through tort law. The reason the DSA succeeded in the EU is not that European courts established a tort template first; it is that the EU has a different regulatory process with different political economy. A has offered no account of why establishing a tort template in the United States will produce better legislative outcomes rather than simply substituting for them permanently. If tort liability becomes a functional substitute for legislation, the pressure to legislate decreases — platforms settle, plaintiffs' firms profit, and the structural problem of algorithmic design standards remains unresolved.

Fourth, A's most direct empirical concession in Round 3 is the most important point in this debate. A states: "I am genuinely uncertain which direction this [safety research incentive] effect will run." That is an honest statement, and I respect it. But it is also a concession that A's framework rests on an empirically uncertain behavioral prediction. My position does not require that prediction to be resolved in my favor — it requires only that the uncertainty is real and that the stakes of being wrong are high enough to prefer the instrument with defined standards and democratic accountability over the instrument with unpredictable jury outcomes and no calibration mechanism. When both the causal science underlying harm claims and the behavioral incentive effects of the liability framework are genuinely uncertain, the burden should fall on the instrument imposing novel liability, not the instrument deferring to deliberative processes.

---

What Specific, Verifiable Evidence Would Change My Mind

I will be concrete, because A has set a good standard for intellectual honesty here.

I would revise my position that the tort template is the wrong instrument if I saw the following specific evidence:

1. Verdict outcome data from the pending MDL cases demonstrating that jury findings track evidentiary quality in a statistically robust way. A named this same condition, and I agree it is the most important empirical test. Specifically: if plaintiff verdict rates in cases with strong internal documentary evidence (board-level communications, suppressed research, explicit risk-benefit trade-off memos) are substantially and statistically distinguishably higher than plaintiff verdict rates in cases relying primarily on expert testimony and platform-general research — say, a 30-percentage-point or greater differential — that would be meaningful evidence that juries are functioning as A claims, adjudicating corporate knowledge rather than narrative. I would need this data from at least 30 resolved cases to have confidence it reflects a pattern rather than noise.

2. Corporate design change evidence showing that the verdict produced targeted behavioral modification rather than broad content restriction. Specifically: if major platforms implement verifiable, auditable algorithmic changes that reduce engagement-optimization weighting for users identified as minors — without corresponding increases in blanket content removal rates for adult users or minority community content — that would be direct evidence against my FOSTA-SESTA over-removal prediction. The key is the specificity of the response: design modification targeted at the tortious mechanism, not categorical removal to minimize exposure.

3. Evidence that the tort template is producing legislative acceleration rather than legislative substitution. If the number of substantive Congressional hearings on algorithmic design standards for minors increases measurably in the 18 months following the verdict, and if platforms reduce lobbying expenditures against KOSA or equivalent legislation — suggesting the verdict has changed their legislative calculus rather than given them a settlement-management alternative to legislation — that would support A's implicit claim that tort liability creates pressure for systemic change rather than substituting for it.

I would not be moved by:

• The observation that tort law has produced behavioral change in other industries, absent evidence that the causal and institutional conditions in those industries are analogous to algorithmic platform design. Grimshaw v. Ford involved a physical product with a discrete, testable failure mode — a fuel tank with documented crash-test data showing known ignition risk. The causal structure is not comparable to multi-step behavioral harm chains mediated by individual psychology.
• The argument that legislative delay justifies judicial substitution, without an account of why tort-template establishment will not simply reduce legislative pressure by providing platforms and plaintiffs with an alternative resolution pathway.
• Further elaboration of internal corporate documents in this specific case, because my objection is to the general template being established, not to whether Meta and YouTube behaved badly in the specific instance. I have never argued they did not.

The condition that would most genuinely change my mind is the first one: systematic MDL outcome data showing verdict rates track evidentiary quality. A named the same condition. That is either a convergence point or the most important empirical question the next three years of litigation will answer. I am prepared to say so explicitly: if that data emerges in A's favor, the institutional competence objection — my strongest argument — will have been falsified in practice, and I will update accordingly.